---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-26-000040"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T18:51:09.697041+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immuneering: FY2025 net loss $56M, cash $217M, 64% OS at 12 months in pancreatic cancer

## Summary
- Net loss for FY2025 was $56.0M ($1.27/share), down from $61.0M ($2.04/share) in 2024.
- Cash and marketable securities $217.0M as of Dec 31, 2025, with anticipated runway into 2029.
- Phase 2a pancreatic cancer data: 64% OS at 12 months for atebimetinib + mGnP, above standard of care 35%.
- Pivotal Phase 3 MAPKeeper 301 on track to dose first patient mid-2026; FDA and EMA alignment secured.
- Plan to dose first patient in Phase 2 trial of atebimetinib + Libtayo in RAS-mutant NSCLC in 2H 2026.

## SEC filing metadata
- accession: 0001790340-26-000040
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034026000040/0001790340-26-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034026000040/imrx-20260306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-26-000040
- JSON: https://secwatch.observer/filing/0001790340-26-000040.json
- Plain text: https://secwatch.observer/filing/0001790340-26-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.